Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Chawla

Showing results (111-120 of 171) with videos related to

Pageof 18
Sort By:
Anticancer Research|June 26, 2024
Proceedings of the Think Tank for Osteosarcoma Medical Advisory BoardSant P Chawla, Brian VAN Tine, Noah Federman, et al.
Cancer|August 24, 2017
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcomaBrian L Samuels, Sant P Chawla, Neeta Somaiah, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trialsF Duffaud, S Sleijfer, S Litière, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Cancer Medicine|May 7, 2020
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United StatesSeth M Pollack, Neeta Somaiah, Dejka M Araujo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?E Palmerini, N S Chawla, S Ferrari, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasJean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
Anticancer Research|September 15, 2019
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse ModelTakashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, et al.
Pageof 18

Showing results (111-120 of 171) with videos related to

Sort By:
Pageof 18
Anticancer Research|June 26, 2024
Proceedings of the Think Tank for Osteosarcoma Medical Advisory BoardSant P Chawla, Brian VAN Tine, Noah Federman, et al.
Cancer|August 24, 2017
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcomaBrian L Samuels, Sant P Chawla, Neeta Somaiah, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trialsF Duffaud, S Sleijfer, S Litière, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Cancer Medicine|May 7, 2020
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United StatesSeth M Pollack, Neeta Somaiah, Dejka M Araujo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?E Palmerini, N S Chawla, S Ferrari, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasJean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
Anticancer Research|September 15, 2019
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse ModelTakashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, et al.
Pageof 18